Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer.
作者信息
O'Shea Anne E, Clifton Guy T, Peoples George E
出版信息
Oncotarget. 2021 Nov 9;12(23):2318-2319. doi: 10.18632/oncotarget.27998.
Abstract
摘要
相似文献
1
Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer.一项将曲妥珠单抗与肽疫苗联合使用的随机试验结果表明，HER2靶向治疗在三阴性乳腺癌中具有一定作用。
Oncotarget. 2021 Nov 9;12(23):2318-2319. doi: 10.18632/oncotarget.27998.
2
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.Nelipepimut-S+曲妥珠单抗对比曲妥珠单抗用于预防高风险 HER2 低表达乳腺癌患者复发的随机 IIb 期试验结果。
Clin Cancer Res. 2020 Jun 1;26(11):2515-2523. doi: 10.1158/1078-0432.CCR-19-2741. Epub 2020 Feb 18.
3
HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment.采用 li-Key 杂合分子、GM-CSF 免疫佐剂和曲妥珠单抗的 HER2/neu 疫苗接种作为一种有效的三阴性乳腺癌治疗方法。
J Cancer Res Clin Oncol. 2023 Aug;149(9):6711-6718. doi: 10.1007/s00432-023-04574-9. Epub 2023 Jan 24.
4
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.尼妥珠单抗联合 GM-CSF 对比单用曲妥珠单抗用于预防高风险、HER2 低表达乳腺癌患者复发的亚组分析。
Clin Immunol. 2021 Apr;225:108679. doi: 10.1016/j.clim.2021.108679. Epub 2021 Jan 22.
5
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.Nelipepimut-S+GM-CSF 和曲妥珠单抗对比单用曲妥珠单抗用于预防低表达 HER2 肿瘤乳腺癌患者复发的随机 II 期试验的初步安全性分析。
Clin Immunol. 2019 Apr;201:48-54. doi: 10.1016/j.clim.2019.02.011. Epub 2019 Feb 25.
6
The development and use of the E75 (HER2 369-377) peptide vaccine.E75（HER2 369-377）肽疫苗的研发与应用。
Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054. Epub 2016 Apr 5.
7
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.HER2肽奈立匹穆-S（E75）疫苗（NeuVax™）用于有复发风险的乳腺癌患者：免疫数据与临床反应的相关性
Immunotherapy. 2014;6(5):519-31. doi: 10.2217/imt.14.22.
8
Immunotherapy as a partner for HER2-directed therapies.免疫疗法作为曲妥珠单抗治疗的伙伴。
Expert Rev Anticancer Ther. 2021 Jul;21(7):739-746. doi: 10.1080/14737140.2021.1894932. Epub 2021 Mar 9.
9
Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data.评估Nelipepimut-S治疗乳腺癌：关于新出现数据的简短报告。
Breast Cancer (Dove Med Press). 2020 Apr 3;12:69-75. doi: 10.2147/BCTT.S224758. eCollection 2020.
10
Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review.曲妥珠单抗治疗后 HER2 状态转换的三阴性乳腺癌患者出现无菌性脓肿样脑部病变：病例报告及文献复习。
BMC Cancer. 2020 Jul 1;20(1):615. doi: 10.1186/s12885-020-07114-7.
引用本文的文献
1
The HER2 target for designing novel multi-peptide vaccine against breast cancer using immunoinformatics and molecular dynamic simulation.利用免疫信息学和分子动力学模拟设计新型抗乳腺癌多肽疫苗的HER2靶点。
Biochem Biophys Rep. 2025 Jul 4;43:102135. doi: 10.1016/j.bbrep.2025.102135. eCollection 2025 Sep.
2
Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges.推进乳腺癌治疗：免疫疗法和癌症疫苗在克服治疗挑战中的作用。
Vaccines (Basel). 2025 Mar 24;13(4):344. doi: 10.3390/vaccines13040344.
本文引用的文献
1
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.恩美曲妥珠单抗联合阿替利珠单抗对比恩美曲妥珠单抗联合安慰剂用于既往治疗、HER2 阳性晚期乳腺癌（KATE2）：一项 2 期、多中心、随机、双盲试验。
Lancet Oncol. 2020 Oct;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4.
2
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.Nelipepimut-S+曲妥珠单抗对比曲妥珠单抗用于预防高风险 HER2 低表达乳腺癌患者复发的随机 IIb 期试验结果。
Clin Cancer Res. 2020 Jun 1;26(11):2515-2523. doi: 10.1158/1078-0432.CCR-19-2741. Epub 2020 Feb 18.
3
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.NSABP B-47/NRG 肿瘤学 III 期随机试验，比较了曲妥珠单抗辅助化疗与无曲妥珠单抗辅助化疗在经 FISH 检测 HER2 阴性、免疫组织化学（IHC）1+或 2+的高危浸润性乳腺癌中的应用。
J Clin Oncol. 2020 Feb 10;38(5):444-453. doi: 10.1200/JCO.19.01455. Epub 2019 Dec 10.
4
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.尼利帕木单抗疫苗预防乳腺癌复发的疗效和安全性分析：一项随机、多中心、III 期临床试验。
Clin Cancer Res. 2019 Jul 15;25(14):4248-4254. doi: 10.1158/1078-0432.CCR-18-2867. Epub 2019 Apr 29.
5
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.帕博利珠单抗联合曲妥珠单抗治疗曲妥珠单抗耐药的晚期 HER2 阳性乳腺癌（PANACEA）：一项单臂、多中心、Ib-2 期试验。
Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.
6
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.曲妥珠单抗通过募集免疫效应细胞和刺激 IFNγ 分泌而上调 PD-L1，成为曲妥珠单抗耐药的潜在机制。
Cancer Lett. 2018 Aug 28;430:47-56. doi: 10.1016/j.canlet.2018.05.009. Epub 2018 May 8.
7
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.一种 HER2 靶向抗体药物偶联物，曲妥珠单抗 deruxtecan（DS-8201a），增强了小鼠模型中的抗肿瘤免疫。
Mol Cancer Ther. 2018 Jul;17(7):1494-1503. doi: 10.1158/1535-7163.MCT-17-0749. Epub 2018 Apr 27.
8
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.曲妥珠单抗可增加树突状细胞对HER2的摄取及交叉提呈。
Cancer Res. 2017 Oct 1;77(19):5374-5383. doi: 10.1158/0008-5472.CAN-16-2774. Epub 2017 Aug 17.
9
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.乳腺癌中的免疫疗法：PD-1和PD-L1的新作用
Curr Oncol Rep. 2017 Aug 10;19(10):64. doi: 10.1007/s11912-017-0627-0.
10
Classical pathology and mutational load of breast cancer - integration of two worlds.经典病理学与乳腺癌的突变负荷——两个世界的融合。
J Pathol Clin Res. 2015 Jul 20;1(4):225-38. doi: 10.1002/cjp2.25. eCollection 2015 Oct.
Zotero 插件